Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 9, 2015 in Coronary artery disease | 0 comments

In a nutshell

This paper studied whether ranolazine (Ranexa) can improve blood flow in patients undergoing percutaneous coronary intervention.

Some background

Angina (chest pain), usually occurs when there is not enough blood flow to the heart. Ranolazine has shown to reduce angina and ischemia (lack of blood flow to the heart). However, the effect of ranolazine in patients who undergo percutaneous coronary intervention is not known. Percutaneous coronary intervention is a procedure done to open up narrowed blood vessels. This improves blood flow to the heart.


Methods & findings

Patients with chronic angina who had an acute coronary syndrome (sudden blockage of blood to the heart) were studied. Patients who underwent percutaneous coronary intervention were compared to patients who did not. Patients were assigned to receive either ranolazine or a placebo (drug that has no real effect). They were followed for 1 year.

After 1 year, 20.3% of patients receiving placebo and 26.4% of patients receiving ranolazine stopped treatment.

Patients who had percutaneous coronary intervention and who received ranolazine were 31% less at risk of another ischemic event than patients who received a placebo. Patients who received ranolazine were 61% less at risk of death from heart causes than patients who received placebo.

In comparison, patients who did not have percutaneous coronary intervention and who received ranolazine were 19% less at risk of another ischemic event than patients who received placebo.

The bottom line

The authors concluded that ranolazine reduced the occurrence of a repeated ischemic event in patients whether or not they had a percutaneous coronary intervention.

The fine print

There were some initial differences in the group of patients who received ranolazine and placebo.

What’s next?

Discuss with your doctor about receiving ranolazine if you are undergoing percutaneous coronary intervention. 

Published By :

Clinical cardiology

Date :

Jun 08, 2015

Original Title :

Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.

click here to get personalized updates